Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10448144" target="_blank" >RIV/00669806:_____/22:10448144 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023736:_____/22:00013440 RIV/65269705:_____/22:00076249 RIV/00098892:_____/22:10157297 RIV/00179906:_____/22:10448144 RIV/00216224:14740/22:00126730

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=p-FJQjhJ9u" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=p-FJQjhJ9u</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2022.2116931" target="_blank" >10.1080/10428194.2022.2116931</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients

Popis výsledku v původním jazyce

Oncogenic mutations in the NRAS gene are carried by 10-22% acute myeloid leukemia (AML) patients and represent one of the most commonly detected molecular aberrations in AML [1-6]. The mutations lead to increased activity of RAS pathway affecting cellular proliferation, survival, and differentiation [7]. NRAS mutations are mainly located in gene hotspots - codons 12, 13 (exon 2) and 61 (exon 3); mutations in other codons are detected rarely [1-5]. The hotspot mutations can be multiple and are often lost during disease progression [1,2,4,8,9]. Although NRAS alterations were first reported in AML more than 30 years ago, their prognostic impact as well as their contribution to malignant transformation remains disputed. The aim of this study was to determine the relevance of single and multiple point NRAS mutations in AML through detailed analysis of well molecularly characterized AML patients.

Název v anglickém jazyce

Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients

Popis výsledku anglicky

Oncogenic mutations in the NRAS gene are carried by 10-22% acute myeloid leukemia (AML) patients and represent one of the most commonly detected molecular aberrations in AML [1-6]. The mutations lead to increased activity of RAS pathway affecting cellular proliferation, survival, and differentiation [7]. NRAS mutations are mainly located in gene hotspots - codons 12, 13 (exon 2) and 61 (exon 3); mutations in other codons are detected rarely [1-5]. The hotspot mutations can be multiple and are often lost during disease progression [1,2,4,8,9]. Although NRAS alterations were first reported in AML more than 30 years ago, their prognostic impact as well as their contribution to malignant transformation remains disputed. The aim of this study was to determine the relevance of single and multiple point NRAS mutations in AML through detailed analysis of well molecularly characterized AML patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV15-25809A" target="_blank" >NV15-25809A: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

1029-2403

Svazek periodika

63

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

3237-3240

Kód UT WoS článku

000848799800001

EID výsledku v databázi Scopus

2-s2.0-85137095711